– USA, MA – Myrobalan Therapeutics, a biotechnology company, announced the appointment of Emma Reeve to its Board of Directors.
“Emma’s wealth of experience in financial matters and her commitment to enabling innovation make her an outstanding addition to our Board of Directors,” said CEO Dr. Jing Wang. “We are excited to leverage her wealth of financial and operational experience as we navigate the next stages of growth.”
About Emma Reeve
Emma Reeve is a seasoned biotech executive with over 30 years of experience in building and leading teams and advancing organizations to value-creating milestones, including IPOs and M&A deals.
Emma Reeve previously served as CFO at Constellation Pharmaceuticals, Inc., a development-stage oncology company that was acquired by MorphoSys AG in 2021. Earlier in her tenure at Constellation, she successfully led the company’s IPO in 2018. Before her time at Constellation, Emma Reeve was the interim CFO and Corporate Controller at Parexel International, a global biopharmaceutical services firm, where she oversaw all finance operations, investor relations, procurement, and facilities management. During her tenure, she played a key role in a sell-side process that resulted in the company’s $5 billion leveraged buyout. Earlier in her career, Emma Reeve held the position of CFO at both Inotek Pharmaceuticals and Aton Pharma, and she also held senior finance and operational roles at Bristol Myers Squibb, Merck, and Novartis.
“I am honored to join Myrobalan’s Board of Directors at such an exciting time. The company’s commitment to neuroscience drug development and its mission to drive positive change for patients living with CNS diseases resonate deeply with me,” said Emma Reeve. “I look forward to working alongside the talented team to navigate the opportunities ahead.”
Emma Reeve is Chair of the Board of Editas Medicine and serves on the Board of PTC Therapeutics and Aadi Bioscience, all public biotechnology companies. In addition, she serves on the Board of Directors for privately owned biotechnology companies, Cardurion Pharma and ReAlta Life Sciences.
Emma Reeve holds a B.Sc. in computer science from Imperial College, University of London, and is an associate of the Institute of Chartered Accountants in England and Wales.
About Myrobalan Therapeutics
Myrobalan Therapeutics is a preclinical-stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, and innovative drug discovery tools, to create highly selective and brain-penetrant therapeutic candidates that are uniquely positioned for treating CNS conditions with significant unmet medical needs. Myrobalan’s pipeline of novel remyelination and anti-neuroinflammation programs is being advanced with the strategic support of renowned institutional co-founders. Myrobalan is committed to a transformed future in which patients with degenerative CNS conditions can access safe and effective medicines offering restorative potential.
For more: https://myrotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.